Decision-making around LVAD therapy vs. optimal medical care for patients with non-inotrope-dependent heart failure has just gotten better-informed. The ROADMAP trial’s lead investigator explains how.
Cleveland Clinic has launched one of the nation’s few outpatient palliative care services for patients with advanced heart disease. We share insights on its purposes and best practices.
The MOMENTUM 3 trial is doing more than assessing the HeartMate 3’s novel mag-lev technology. It also reflects the fading distinction between bridge and destination LVAD therapy.
Heart experts at Cleveland Clinic recommend referring patients for a mechanical device (i.e., the LVAD) earlier and outside the context of transplantation. The devices can help improve quantity and quality of life for heart failure patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Acute kidney injury is a common post-heart transplant complication. Could a heart transplant candidate’s renal response to left ventricular assist device placement – a common bridge to transplant – foretell who’s at risk for post-transplant AKI?
Left-ventricular assist devices (LVADs) are a viable alternative to transplant for some patients, and today s smaller devices make these an option for more patients with heart failure
Peripartum cardiomyopathy should always be considered a differential diagnosis when a woman who is in her last trimester or who has recently delivered develops progressive dyspnea, edema and weight gain or right upper-quadrant fullness mimicking cholecystitis.